Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition of levodopa/benserazide/folic acid compounds and purpose thereof

A technology of levodopa and a composition, which is applied in the field of pharmacy and achieves the effects of convenience in taking medicine, overcoming low drug efficacy and reducing cerebral apoplexy

Inactive Publication Date: 2013-06-05
SUZHOU FAMO BIOLOGICAL TECH
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Entocapone is 100-200 mg each time, and the frequency of taking the compound levodopa is the same as that of the compound levodopa. Levodopa taken together, single use is invalid

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition of levodopa/benserazide/folic acid compounds and purpose thereof
  • Pharmaceutical composition of levodopa/benserazide/folic acid compounds and purpose thereof
  • Pharmaceutical composition of levodopa/benserazide/folic acid compounds and purpose thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Embodiment 1. Preparation of tablet

[0035] prescription:

[0036]

[0037] Preparation Process:

[0038] (1) Take the levodopa, benserazide and folic acid of the prescribed amount and pass through a 100-mesh sieve and mix them uniformly by the method of equal increments for subsequent use;

[0039] (2) Other auxiliary materials are passed through a 100-mesh sieve and dried at 75°C for 2 hours;

[0040] (3) Mix the starch, microcrystalline cellulose, and CMS.Na according to the prescription amount, and then mix them evenly with the mixed raw material drug in equal increments;

[0041] (4) Add an appropriate amount of binder to prepare soft materials, granulate with a 24-mesh sieve, granulate with a 20-mesh sieve, and dry at 40-75°C.

[0042] (5) Add an appropriate amount of magnesium stearate to the dry granules and mix evenly. After the content is determined, compress into tablets and pack.

[0043] 3 times a day, 1 tablet each time.

Embodiment 2

[0044] Embodiment 2. The preparation of capsule

[0045] prescription:

[0046]

[0047] Preparation Process:

[0048] According to the prescription ratio, take lactose, microcrystalline cellulose, starch, and carboxymethyl starch sodium and dry them at about 100°C for about 2 hours, pass through a 100-mesh sieve; pass the raw material through a 100-mesh sieve, and increase the amount of the above-mentioned excipients in equal increments Mix well and fill the capsules.

[0049] 3 times a day, 1 capsule each time.

Embodiment 3

[0050] Example 3. Preparation of Sustained Release Tablets

[0051] prescription:

[0052]

[0053] Preparation Process:

[0054] According to the proportion of the prescription, the raw material is mixed with hypromellose, citric acid is dissolved in ethanol as a wetting agent to make a soft material, granulated, dried, sized, mixed with magnesium stearate, pressed Slice and serve.

[0055] 1 time every other day, 1-2 tablets each time.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutical composition of levodopa / benserazide / folic acid compounds and a purpose thereof, and belongs to the technical field of pharmacy. The pharmaceutical composition comprises the levodopa with medical dose, the benserazide with the medical dose, the folic acid compounds with the medical dose and a carrier which can be accepted in the pharmacy. The dose of the levodopa is 100-300 mg, the dose of the benserazide is 30-70 mg, and the dose of the folic acid compounds is 0.2-1.6 mg. The pharmaceutical composition of the levodopa / the benserazide / the folic acid compounds and the purpose thereof have the advantages of enhancing the curative effect of Parkinson disease resistance and improving the quality of life of a patient through the synergistic effect of multiple target points; being capable of effectively preventing and lowering the occurring risk of cerebral apoplexy of a Parkinson disease patient through a homocysteine (Hcy) target point; and in addition, enabling the patient to take medicine conveniently.

Description

technical field [0001] The invention relates to a pharmaceutical composition of levodopa / benserazide / folic acid compound and its application, belonging to the technical field of pharmacy. Background technique [0002] Parkinson's disease (PD) is a chronic progressive disease of extrapyramidal dysfunction in the central nervous system. The main pathological manifestations of PD are the degeneration of dopamine (DA) neurons in the substantia nigra, and the decrease of the content of central neurotransmitter DA, and the degree of depletion of DA is consistent with the severity of PD; at the same time, it can also be accompanied by acetylcholine (Ach), 5- Abnormality and imbalance of various neurotransmitters such as serotonin (5-HT), norepinephrine (NE), γ-aminobutyric acid, and neuropeptides, resulting in a series of clinical symptoms, such as muscle tremors, stiffness, and postural disturbances , movement difficulties, etc. According to reports, there are about 1.5 million ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/519A61K31/198A61K31/165A61P25/16
Inventor 王玉姝
Owner SUZHOU FAMO BIOLOGICAL TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com